Register for free to listen to this article
Listen with Speechify
0:00
1:00
CHIBA, Japan—Transparent Inc., a provider of 3D cell cultureplate design and applications, and Molecular Response Laboratories (MRL), aprivately held molecular diagnostic services company, announced in late Marchthat they launch Cell-able Oncology, a novel 3D cell culture system forpharmaceutical researchers and medical professionals.
 
Cell-able Oncology combines Transparent's 3D cell cultureplate design and manufacturing technologies and MRL's proprietary bank of"living" tumor cells and quantitative high-content platforms. The platform willbe marketed under Transparent's "Cell-able Oncology" brand, with key contractresearch support for preclinical and clinical trial applications by MRL.
 
 
According to the companies, current strategies fordeveloping new anticancer drugs rely heavily on preclinical testing in cancercell lines and their derived in-vivoxenograft models. A significant limitation to current preclinical testing isthe use of highly passaged cancer cell lines grown on plastic. Improvedpreclinical models are required to advance understanding of the molecularaberrations that underpin cancer.
 
Cell-able Oncology will allow primary tumor cells to grow in3D cultures that more closely resemble in-vivo-like conditions. Models grown in 3D culture conditions coupled withmolecular characterization provide a stronger correlation to clinical outcomesthan conventional preclinical anticancer drug testing, the companies say.
 
"Molecular Response's pharmaceutical research services,combined with Cell-able Oncology, will provide researchers the right tools toperform transformative drug discovery with patient-derived primary tumor cellsand focused molecular targets that enable drug sensitivity testing that isstrongly correlated to clinical outcomes," said Transparent CEO Rocky Kato in astatement.
Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gold circles with attached purple corkscrew shapes represent gold nanoparticles against a black background.

Driving gene therapy with nonviral vectors 

Learn why nonviral vectors are on the rise in gene therapy development.
A 3D digital illustration of a viral spike protein on a cell surface, surrounded by colorful, floating antibodies in the background

Milestone: Leapfrogging to quantitative, high throughput protein detection and analysis

Researchers continuously push the boundaries of what’s possible with protein analysis tools.
Blue cancer cells attached to a cellular surface against a bright blue background in a 3D rendering of a cancer infection.

Advancing immuno-oncology research with cellular assays

Explore critical insights into immunogenicity and immunotoxicity assays for cancer therapies.
Drug Discovery News November 2024 Issue
Latest IssueVolume 20 • Issue 6 • November 2024

November 2024

November 2024 Issue

Explore this issue